The case for & against
Bull & Bear analysis
Bearish
Tenax Therapeutics, Inc. (NASDAQ:TENX) is a biopharmaceutical company focused on developing innovative treatments for pulmonary hypertension and heart failure, specifically with its lead product, TNX-103. This oral formulation of levosimendan aims to address the unmet medical needs of patients suffering from pulmonary hypertension with preserved ejection fraction (PH-HFpEF). Positioned within the growing therapeutic landscape of heart failure management, Tenax is currently advancing its clinical programs through late-stage trials, with most expectations centered on the outcomes of the pivotal Phase 3 LEVEL study.
Bull says
- ↑$118.8M cash reserve provides funding through Q1 2028.
- ↑Phase 3 LEVEL trial readout in Aug 2026 may trigger FDA filing.
- ↑Analyst consensus is Moderate Buy with $38 average price target.
- ↑PH-HFpEF market is underserved; TNX-103 has first-in-class potential.
- ↑High institutional interest seen in strong 13F ownership factor.
- ↑Positive liquidity and momentum factors support trading activity.
Bear says
- ↓Reliance on Phase 3 data creates binary outcome risk.
- ↓Negative earnings yield and weak profitability factors indicate poor returns.
- ↓High leverage risk may strain finances amid rising interest rates.
- ↓Negative revisions and flat growth metrics show shrinking expectations.
- ↓Market access and reimbursement hurdles could delay TNX-103 launch.
- ↓Short interest at 7% (up 132.9%) reflects deep investor skepticism.
Earnings Call · Q3 2025 · Mgmt. Guidance
Updated 07-16-2026neutral
Transcript signals
Bull points
- the fact that we now can do this with a pill is incredible. And as this, you know, slide 15 shows that, you know, even above and beyond the IV, the pill was not only maintaining the benefits that we saw in the acute trial, but actually improving upon that.
- it's really been life-altering for many people.
- the fact that we now can do this with a pill is incredible. And as this, you know, slide 15 shows that, you know, even above and beyond the IV, the pill was not only maintaining the benefits that we saw in the acute trial, but actually improving upon that.
Bear points
- This is just an exploratory safety analysis here, but this is showing a 2.6-fold non-significant increased risk in heart failure hospitalization in patients who were with HFpEF who were treated with volant relaxin as compared to placebo.
- We saw decreases in hematocrit indicating dilution of the blood from water overload, and worsening congestion. We saw an increase in NT-proBNP level, which is a biomarker that's reflective of fluid status. Patients were less likely to have an improvement in functional class. It was really a consistent bad message across the board.
- This is just an exploratory safety analysis here, but this is showing a 2.6-fold non-significant increased risk in heart failure hospitalization in patients who were with HFpEF who were treated with volant relaxin as compared to placebo.
Read full transcript analysis ›